Cambrex to Double Size of Edinburgh Solid Form Screening Facility
30 Juillet 2019 - 2:00PM
Cambrex Corporation (NYSE: CBM), the leading small molecule company
providing drug substance, drug product and analytical services
across the entire drug lifecycle, today announced that it is
expanding its solid form screening and crystallization process
development facility in Edinburgh, Scotland, doubling the current
footprint to 15,000 sq. ft. The site currently has 50 employees and
the expansion will add additional laboratory space to enable the
recruitment of up to 40 more scientists, with the potential for
further growth in the future.
Fit out is expected to begin in late August 2019
with a target completion date of the end of the year.
Cambrex’s Edinburgh site is a world-leader in
providing solid form development services for drug substance and
drug product. These include solid state investigations such as
salt, co-crystal and polymorph screening, in addition to
crystallization process development and GMP analytical
services.
The expanded laboratory space will allow the
installation of additional instruments and reactors for larger
scale crystallization studies and solid form screening
capabilities. Plans are in place for the installation of new
ultra-performance liquid chromatography (UPLC) and gas
chromatography instruments, as well as additional process
analytical technology (PAT) tools.
“This strategic expansion, the increase in
headcount and the investment in new equipment will enable us to
serve more customers in the solid state screening market,”
commented Mark Benger, Edinburgh Site Director, Cambrex. He added,
“We have increasingly been asked by clients for additional services
such as larger scale crystallization and we will now be able to
provide these as well as adding greater efficiency and capacity at
the Edinburgh site.”
Edinburgh became part of Cambrex’s global
network of development and manufacturing facilities after the
acquisition of Avista Pharma Solutions earlier this year. The
facility was formerly known as Solid Form Solutions, an industry
leader in solid state services, prior to the acquisition.
About Cambrex
Cambrex is the leading small molecule company
that provides drug substance, drug product and analytical services
across the entire drug lifecycle. The company provides customers
with an end-to-end partnership for the research, development and
manufacture of small molecule therapeutics. With over 35 years’
experience and a growing team of over 2,000 experts servicing
global clients from sites in North America and Europe, Cambrex is a
trusted partner in branded and generic markets for API and dosage
form development and manufacturing.
Cambrex offers a range of specialist drug
substance technologies and capabilities including biocatalysis,
continuous flow, controlled substances, solid state science,
material characterization and highly potent APIs. In addition,
Cambrex can support conventional dosage forms including oral
solids, semi-solids and liquids and has the expertise to
manufacture specialist dosage forms such as modified-release, fixed
dose combination, pediatric, bi-layer tablets, stick packs,
topicals, controlled substances, sterile and non-sterile
ointments.
For more information, please visit
www.cambrex.com
Contact:Alex MawDirector, Marketing and CommunicationsTel: +44
7803 443 155Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Cambrex (NYSE:CBM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024